GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

Ablynx and Boehringer Ingelheim Embark on $265M Alzeimer’s Collaboration

  • Boehringer Ingelheim and Ablynx inked a deal worth almost $265 million to discover and develop new therapies for Alzheimer’s disease. The worldwide collaboration and license agreement will use Ablynx’ Nanobodies®, a novel class of therapeutic proteins.

    In addition Boehringer Ingelheim will commence a joint research program with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture, and commercialization of any products resulting from the collaboration. The deal includes an upfront fee, development and commercial milestones., and sales-based royalties.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Genetics and Intelligence

Do you believe research on the genetics of intelligence can improve education?

More »